Marcin Mikołaj Grzybowski - OncoArendi Therapeutics, Warsaw, Poland

基本信息

Career Trajectory

Bio

My current professional interests focus on drug discovery with an emphasis on immuno-oncology preclinical studies. I am mostly experienced in the methodology of animal research including tumour models. My scientific background covers also preclinical vaccine development, medical microbiology and infectious immunology. I believe that team-building skills are among my important strengths.

Research Interests

Papers共 46 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Novel Orally Bioavailable Piperidine Derivatives As Extracellular Arginase Inhibitors Developed by a Ring Expansion

Anna Gzik,Bartlomiej Borek,Jacek Chrzanowski,Karol Jedrzejczak,Marek Dziegielewski,Joanna Brzezinska,Julita Nowicka,Marcin M. Grzybowski,Tomasz Rejczak,Dorota Niedzialek,Grzegorz Wieczorek, Jacek Olczak,Adam Golebiowski,Zbigniew Zaslona,Roman Blaszczyk

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY（2024）

Cited0Views0WOSBibtex

Supplementary Figure 15 from Arginase 1/2 Inhibitor OATD-02: from Discovery to First-in-man Setup in Cancer Immunotherapy

Bartlomiej Borek,Julita Nowicka,Anna Gzik,Marek Dzięgielewski,Karol Jedrzejczak,Joanna Brzezinska,Marcin Grzybowski,Paulina Stanczak,Paulina Pomper,Agnieszka Zagożdżon,Tomasz Rejczak,Krzysztof Matyszewski, Adam Golebiowski, Jacek Olczak,Kamil Lisiecki,Magdalena Tyszkiewicz,Magdalena Kania,Sylwia Piasecka,Anna Cabaj,Paulina Dera,Krzysztof Mulewski,Jacek Chrzanowski,Damian Kusmirek,Elżbieta Sobolewska,Marta Magdycz,Lukasz Mucha, Marek Masnyk, Jakub Gołąb, Marcin Nowotny,Elżbieta Nowak,Agnieszka Napiórkowska-Gromadzka, Stanislaw Pikul,Radosław Jaźwiec,Karolina Dzwonek, Pawel Dobrzanski,Michael Meyring, Krzysztof Skowronek,Piotr Iwanowski,Zbigniew Zasłona,Roman Błaszczyk

openalex（2023）

Cited0Views0Bibtex

Supplementary Figure 21 from Arginase 1/2 Inhibitor OATD-02: from Discovery to First-in-man Setup in Cancer Immunotherapy

openalex（2023）

Cited0Views0Bibtex

Supplementary Figure 21 from Arginase 1/2 Inhibitor OATD-02: from Discovery to First-in-man Setup in Cancer Immunotherapy

openalex（2023）

Cited0Views0Bibtex

717Tip an Open-Label, Multicentre, Dose-Escalation, First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 (dual Arginase 1 and Arginase 2 Inhibitor) in Patients with Selected Advanced And/or Metastatic Solid Tumors

M.A. Dudek,Z. Zasłona,R. Błaszczyk,M.M. Grzybowski,T. Rejczak, A. Cabaj, P. Dera, K. Lisiecki, P. Iwanowski, T. Charitos, S. Fung

Annals of Oncology (2023): S495

Cited0Views0Bibtex

Supplementary Materials and Methods from Arginase 1/2 Inhibitor OATD-02: from Discovery to First-in-man Setup in Cancer Immunotherapy

openalex

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn